Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 12/2012

01-12-2012 | Original Article

Short post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia

Authors: C. J. G. van den Hurk, W. P. M. Breed, J. W. R. Nortier

Published in: Supportive Care in Cancer | Issue 12/2012

Login to get access

Abstract

Purpose

The patient impact of chemotherapy-induced alopecia (CIA) is high. Scalp cooling is applied to reduce CIA. The potential optimum post-infusion cooling times (PICTs) are currently unknown.

Methods

Scalp cooling was applied in 53 patients receiving docetaxel chemotherapy with 90-min PICT (observational part). Also 15 non-scalp-cooled patients were included. If hair preservation was observed in >80 % of the patients, randomisation between 45 and 90-min PICT was planned. Patients reported tolerance of scalp cooling and use of head covering.

Results

Observational study: 81 % of scalp-cooled patients did not require head covering versus 27 % of non-scalp-cooled patients. Randomised study: 79 % of 38 patients with 90-min PICT did not need head covering versus 95 % of 38 patients with 45-min PICT (p = 0.04). Scalp cooling was very well tolerated (visual analogue scale = 79).

Conclusion

A 45-min PICT can be recommended in 3-weekly docetaxel regimens with a dose of 75 or 100 mg/m2, administered in 60 min. The shorter PICT is a major advantage in time investment for patients. Patients (women and men) who receive docetaxel, except combined with doxorubicin and cyclophosphamide (taxotere, adriamycin and cyclophosphamide (TAC)) should be informed about the protective effect and high tolerability of scalp cooling in avoiding CIA.
Literature
1.
Grevelman EG, Breed WP (2005) Prevention of chemotherapy-induced hair loss by scalp cooling. Ann Oncol 16:352–358PubMedCrossRef
2.
Breed WPM, van den Hurk CJG, Peerbooms M (2011) Presentation, impact and prevention of chemotherapy-induced hair loss; scalp cooling potentials and limitations. Expert Rev Dermatol 6:109–125CrossRef
3.
Christodoulou C, Klouvas G, Efstathiou E et al (2002) Effectiveness of the MSC cold cap system in the prevention of chemotherapy-induced alopecia. Oncology 62:97–102PubMedCrossRef
4.
Katsimbri P, Bamias A, Pavlidis N (2000) Prevention of chemotherapy-induced alopecia using an effective scalp cooling system. Eur J Cancer 36:766–771PubMedCrossRef
5.
Lemenager M, Lecomte S, Bonneterre ME et al (1997) Effectiveness of cold cap in the prevention of docetaxel-induced alopecia. Eur J Cancer 33:297–300PubMedCrossRef
6.
Lundgren-Eriksson L, Edbom G, Olofsson Y et al (1999) Total prevention of taxoid-induced alopecia by a new model of cold cap (dignitana). Eur J Cancer 35(suppl 4):376CrossRef
7.
Auvinen PK, Mahonen UA, Soininen KM et al (2010) The effectiveness of a scalp cooling cap in preventing chemotherapy-induced alopecia. Tumori 96:271–275PubMed
8.
Ridderheim M, Bjurberg M, Gustavsson A (2003) Scalp hypothermia to prevent chemotherapy-induced alopecia is effective and safe: a pilot study of a new digitized scalp-cooling system used in 74 patients. Support Care Cancer 11:371–377PubMed
9.
ElGenidi M (2001) Prevention of chemotherapy-induced alopecia by the new digital scalp cooler device. Eur J Cancer 37(Suppl 6):357CrossRef
10.
Massey CS (2004) A multicentre study to determine the efficacy and patient acceptability of the Paxman Scalp Cooler to prevent hair loss in patients receiving chemotherapy. Eur J Oncol Nurs 8:121–130PubMedCrossRef
11.
12.
Middleton J, Franks D, Buchanan RB et al (1985) Failure of scalp hypothermia to prevent hair loss when cyclophosphamide is added to doxorubicin and vincristine. Cancer Treat Rep 69:373–375PubMed
13.
Hilton S, Hunt K, Emslie C et al (2008) Have men been overlooked? A comparison of young men and women’s experiences of chemotherapy-induced alopecia. Psycho-Oncology 17:577–583PubMedCrossRef
14.
Baxley KO, Erdman LK, Henry EB, Roof BJ (1984) Alopecia: effect on cancer patients’ body image. Cancer Nurs 7:499–503PubMedCrossRef
15.
de Boer-Dennert M, de Wit R, Schmitz PI et al (1997) Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76:1055–1061PubMedCrossRef
16.
Tabernero J, Climent MA, Lluch A et al (2004) A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 15:1358–1365PubMedCrossRef
17.
Ravdin PM, Burris HA 3rd, Cook G et al (1995) Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879–2885PubMed
18.
Marty M, Cognetti F, Maraninchi D et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23:4265–4274PubMedCrossRef
19.
O’Shaughnessy J, Miles D, Vukelja S et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812–2823PubMedCrossRef
20.
Sjostrom J, Blomqvist C, Mouridsen H et al (1999) Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35:1194–1201PubMedCrossRef
21.
Chan S, Friedrichs K, Noel D et al (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341–2354PubMed
22.
Chevallier B, Fumoleau P, Kerbrat P et al (1995) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13:314–322PubMed
23.
Bonneterre J, Roche H, Monnier A et al (2002) Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 87:1210–1215PubMedCrossRef
24.
Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512PubMedCrossRef
25.
Fossella F, Pereira JR, von Pawel J et al (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21:3016–3024PubMedCrossRef
26.
Chang HR, Glaspy J, Allison MA et al (2010) Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer 116:4227–4237PubMedCrossRef
27.
van den Hurk CJ, Peerbooms M, van de Poll-Franse LV, Nortier JW, Coebergh JW, Breed WP (2012) Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients - Results of the Dutch Scalp Cooling Registry. Acta Oncol 51(4):497–504
Metadata
Title
Short post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia
Authors
C. J. G. van den Hurk
W. P. M. Breed
J. W. R. Nortier
Publication date
01-12-2012
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 12/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1465-0

Other articles of this Issue 12/2012

Supportive Care in Cancer 12/2012 Go to the issue

Original Article

French version of the Functional Assessment of Cancer Therapy–Cognitive Function (FACT-Cog) version 3

Review Article

Randomised controlled trials of yoga interventions for women with breast cancer: a systematic literature review

Original Article

The cancer outpatient satisfaction with care questionnaire for chemotherapy, OUT-PATSAT35 CT: a validation study for Spanish patients

Original Article

Accrual in supportive care trials in pediatric oncology, a challenge!

Original Article

Prevalence and severity of suffering among patients with advanced cancer

Short Communication

Low body mass index as a risk factor of moderate to severe oral mucositis in oral cancer patients with radiotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits